C-MGFMTNF Pharmaceuticals (was MyMD)
biotech pharmaceuticals, MYMD-1, Supera-CBD
modulatingsmall molecule
Loading
Загрузка раздела...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-MGFM
C-MGFMC-MGFMbiotech pharmaceuticals, MYMD-1, Supera-CBD
0-100 chain-logic scale · 15 dimensions · scored on public evidence
TNF Pharmaceuticals (was MyMD) biotech pharmaceuticals, MYMD-1, Supera-CBD
TNF Pharmaceuticals, formerly MyMD Pharmaceuticals, presents itself as a biotech pharmaceutical company. The site lists pipeline programs MYMD-1 and Supera-CBD, along with research and clinical trials sections. A September 2, 2025 press release says TNF Pharmaceuticals entered a licensing agreement with LightSolver for computing technology in cryptocurrency and blockchain applications.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
TNF Pharmaceuticals (was MyMD) — Translational · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic